MedImmune and Micromet AG, a wholly owned subsidiary of Micromet, Inc., will receive a milestone payment from MedImmune triggered by the IND filing. Micromet’s Proprietary BiTEĀ® Platform has Potential to Improve Treatment in Multiple Tumor Types. All-Cash Transaction Values Micromet at. The initial development plan contemplates EUR 25 million in funding of Micromet R&D activities if two BiTE antibodies are advanced to IND.

Author: Tojazuru Galrajas
Country: Great Britain
Language: English (Spanish)
Genre: Personal Growth
Published (Last): 14 November 2013
Pages: 361
PDF File Size: 1.86 Mb
ePub File Size: 2.63 Mb
ISBN: 443-4-43370-664-6
Downloads: 65192
Price: Free* [*Free Regsitration Required]
Uploader: Vojora

Micromet will be primarily responsible for the discovery and preclinical development of the BiTE antibodies. Currently, we have a Neutral recommendation on Micromet. Micromet is responsible for the development and commercialization of the candidate inEurope. Two product candidates are currently in clinical trials.

Amgen Pays $10M Up Front in Cancer Deal with Micromet

They have been directed to keep nebulizers and other related equipment in good condition and to be ready to meet with any exigency, the ministry stated in a release. For the second BiTE program, Micromet is eligible to receive an additional cash payment upon initiation of the program, milestones, royalties, and development funding comparable to the first program.

MT is being developed in collaboration with Serono. Top 10 Pharma Companies of The air conditioning system in the new Tesla Model X has three modes: Learn how your comment data is processed.


Good News for Micromet

By continuing to use our site, you are agreeing to the use of cookies as set in our privacy policy. Under the terms of the deal, MedImmune is responsible micrommet the development and commercialization of the candidate in the US and outside Europe. National Entrepreneurship Awards Dental treatments burning a hole in your pocket?

Expands Management and Appoints Christopher P. Health minister tells Delhi hospitals to prepare for rise in patients with respiratory illnesses 10 Nov, Dec 31, In inx presence of BiTE antibodies, T cells have been demonstrated to serially eliminate tumor cells, which explains the activity of BiTE antibodies at very low concentrations.

Prior to that, Mr. Top 10 Molecular Millionaires of This is the second highest pollution level of this year. This release contains certain forward-looking statements that involve risks and uncertainties that could micromdt actual results to be materially different from historical results or from any future results expressed or implied by such forward-looking statements. In Zacks originated the concept of utilizing earnings estimates revisions to make profitable investment decisions.

Alder received an LL.

Micromet Announces Solid Tumor BiTE Antibody Collaboration with Amgen | FierceBiotech

These factors and others are more fully discussed in our periodic reports and other filings with the SEC. The candidate is being developed to treat patients suffering from advanced gastrointestinal cancers.


Through the killing process, T cells start to proliferate, which leads to an increased number of T cells at the site of knd. Schnittker received his B.

Micromet: Latest News & Videos, Photos about Micromet | The Economic Times

Government 4 Jul, We note that the most promising candidate at Micromet is blinatumomab MTalso being co-developed with MedImmune, for the treatment of acute lymphoblastic leukemia ALLa type of blood cancer. The platform represents a novel approach for treating cancers.

Micromet and Amgen micromt a deal under which Micromet will work to discover antibodies against three undisclosed tumor targets from Amgen. In addition to the finance, business development and legal functions, Micromet is planning to expand the US headquarters by adding a development team for Micromte clinical trials and regulatory interactions with the FDA.

Commercializing Continuous Processing in Pharma. The new biogenic products can rebuild teeth and cure cavities without costly and uncomfortable treatments. We are open to mucromet merger options: Micromet will leverage its BiTE technology, and Amgen will have the right to pursue development and commercialization of compounds for up to two of these targets.